Literature DB >> 30653275

Heparanase-1 activity and the early postnatal prostate development.

Guilherme Oliveira Barbosa1, Alexandre Bruni-Cardoso2, Maria Aparecida da Silva Pinhal3, Taize Machado Augusto4, Hernandes F Carvalho1.   

Abstract

Ventral prostate (VP) morphogenesis starts during embryonic development and continues for the first three postnatal weeks. Heparan sulfate (HS) affects paracrine signaling. Heparanase-1 (HPSE) is the only enzyme capable of cleaving HS. HPSE releases the HS bioactive fragment and mobilizes growth factors. Little is known, however, about HS turnover and HPSE function during VP morphogenesis. In this study, we measured HSPG expression and analyzed the expression and distribution of HPSE in the rat VP. HPSE was predominantly expressed by the VP epithelium. The VP was treated with heparin in ex vivo cultures to interfere with HS and resulted in delayed epithelial growth. Hpse knockdown using siRNA delayed epithelial growth in the first postnatal week ex vivo, which was similar to treating with the lower concentration of heparin. Hpse silencing was related to changes in HS chain length (as determined by size-exclusion chromatography, up-regulation of Mmp9, and down-regulation of Mmp2 expression). It also down-modulated ERK1/2 phosphorylation, suggesting a reduction in signaling, likely due to decreased HS cleavage and growth factor bioavailability. Our results showed that HPSE played a role in early epithelial growth during the first week of VP postnatal development. Developmental Dynamics 248:211-220, 2019.
© 2019 Wiley Periodicals, Inc. © 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Development; epithelial morphogenesis; heparan sulfate; heparanase; prostate

Year:  2019        PMID: 30653275     DOI: 10.1002/dvdy.12

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  3 in total

1.  Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies.

Authors:  Seungwon An; Ilangovan Raju; Bayasgalan Surenkhuu; Ji-Eun Kwon; Shilpa Gulati; Muge Karaman; Anubhav Pradeep; Satyabrata Sinha; Christine Mun; Sandeep Jain
Journal:  Ocul Surf       Date:  2019-04-06       Impact factor: 5.033

Review 2.  Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.

Authors:  Nicola J Nasser; Jonathan Klein; Abed Agbarya
Journal:  Adv Radiat Oncol       Date:  2020-10-27

3.  Heparanase-1 facilitates bone remodeling on bone defect animal model with optimal dosage and treatment duration.

Authors:  Jir-You Wang; Cheng-Fong Chen
Journal:  J Chin Med Assoc       Date:  2020-09       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.